Company Encyclopedia
View More
name
JOINN
06127.HK
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People’s Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies.
720.18 B
06127.HKMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking9/14
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE2.79%C
    • Profit Margin13.49%B
    • Gross Margin33.88%C
  • Growth ScoreD
    • Revenue YoY-22.29%E
    • Net Profit YoY24505.09%A
    • Total Assets YoY-1.29%D
    • Net Assets YoY0.23%C
  • Cash ScoreD
    • Cash Flow Margin741.10%B
    • OCF YoY-22.29%E
  • Operating ScoreD
    • Turnover0.18D
  • Debt ScoreA
    • Gearing Ratio14.81%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Joinn Laboratories Books 80% Lower Profit in Q3

    Joinn Laboratories Books 80% Lower Profit in Q3

    marketscreener·
    HK
    06127
    -4.36%
    SH
    603127
    -3.30%
    marketscreener·
    HK
    06127
    -4.36%
    SH
    603127
    -3.30%

    Hong Kong stocks in the innovative drug concept sector continue to strengthen, with RemeGen rising over 8%

    Hong Kong stocks related to innovative pharmaceuticals continue to strengthen, with RemeGen rising over 8%, INNOVENT BIO rising over 7%, and FOSUN PHARMA, JUNSHI BIO, and JOINN rising over 5%

    Zhitong·
    SH
    600196
    -0.91%
    HK
    02196
    -1.58%
    SH
    688180
    -1.92%
    Zhitong·
    SH
    600196
    -0.91%
    HK
    02196
    -1.58%
    SH
    688180
    -1.92%

    Founder Securities: A new round of upward movement in the pharmaceutical industry has begun, focusing on early research and the new trend of CRO industry outsourcing

    Fangzheng Securities released a research report indicating that the pharmaceutical and biotechnology industry has entered a new upward cycle, and the recovery of financing for innovative drugs will drive the growth of clinical projects. It is recommended to pay attention to upstream companies in the biotechnology sector with strong overseas capabilities and the early research CRO industry chain, believing that the domestic early research industry chain will benefit from the recovery of overseas demand. It is expected that the price of experimental monkeys will remain stable with a slight increase in the short term, and the prospects for upstream biological products going overseas are broad

    Zhitong·
    HK
    02315
    -1.41%
    SZ
    301080
    -1.32%
    SZ
    300759
    -1.80%
    Zhitong·
    HK
    02315
    -1.41%
    SZ
    301080
    -1.32%
    SZ
    300759
    -1.80%
    Posts
    View More